Application
ID3 Antibody (N-term) western blot analysis in mouse kidney tissue lysates (35ug/lane).This demonstrates the ID3 antibody detected the ID3 protein (arrow).| Product Name | ID3 Antibody (N-term) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | ID3; 1R21; BHLHB25; HEIR1; DNA-binding protein inhibitor ID-3; Class B basic helix-loop-helix protein 25; Helix-loop-helix protein HEIR-1; ID-like protein inhibitor HLH 1R21; Inhibitor of DNA binding 3 |
| Clonality | Polyclonal |
|---|---|
| Isotype | Ig |
| Host Species | Rabbit |
| Tested Applications | WB |
| WB:1:100~500 |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Gene Synonyms | 1R21 BHLHB25 HEIR1 |
|---|---|
| Alternative Names | ID3 1R21 BHLHB25 HEIR1 DNA-binding protein inhibitor ID-3 Class B basic helix-loop-helix protein 25 Helix-loop-helix protein HEIR-1 ID-like protein inhibitor HLH 1R21 Inhibitor of DNA binding 3 |
| Molecular Weight(MW) | 12999 Da |
| Function | ID (inhibitor of DNA binding) HLH proteins lack a basic DNA-binding domain but are able to form heterodimers with other HLH proteins, thereby inhibiting DNA binding. ID-3 inhibits the binding of E2A-containing protein complexes to muscle creatine kinase E-box enhancer. May inhibit other transcription factors |
| Tissue Specificity | Expressed abundantly in lung, kidney and adrenal gland, but not in adult brain |
| Cellular Localization | Nucleus. |
| Entrez Gene | 3399 |
|---|---|
| Nucleotide Accession | NP_002158.3 |
Application
ID3 Antibody (N-term) western blot analysis in mouse kidney tissue lysates (35ug/lane).This demonstrates the ID3 antibody detected the ID3 protein (arrow).| Application Notes | WB:1:100~500 |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
